Published in Gastroenterology on August 04, 2010
Cheno Effect on Transit in Health and IBS-C (Chenotransit) | NCT00912301
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
Regulators of Gut Motility Revealed by a Gnotobiotic Model of Diet-Microbiome Interactions Related to Travel. Cell (2015) 2.26
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
Validating biomarkers of treatable mechanisms in irritable bowel syndrome. Neurogastroenterol Motil (2014) 2.11
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology (2011) 1.22
Bowel functions, fecal unconjugated primary and secondary bile acids, and colonic transit in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2013) 1.20
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol (2012) 1.19
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol (2013) 1.12
The role of genetics in IBS. Gastroenterol Clin North Am (2011) 1.07
Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med (2015) 1.06
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver (2011) 0.99
Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol (2012) 0.99
Brain-gut axis: from basic understanding to treatment of IBS and related disorders. J Pediatr Gastroenterol Nutr (2012) 0.96
Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr (2016) 0.94
Microflora modulation of motility. J Neurogastroenterol Motil (2011) 0.91
Advances in understanding of bile acid diarrhea. Expert Rev Gastroenterol Hepatol (2013) 0.91
Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol (2015) 0.91
Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci (2012) 0.90
Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil (2011) 0.90
Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation. J Neurogastroenterol Motil (2014) 0.88
Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea. Am J Gastroenterol (2016) 0.87
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol (2014) 0.86
Chronic constipation: new diagnostic and treatment approaches. Therap Adv Gastroenterol (2012) 0.85
Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit. Am J Physiol Gastrointest Liver Physiol (2013) 0.80
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver (2015) 0.79
Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption. Clin Gastroenterol Hepatol (2016) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations. Dig Dis Sci (2012) 0.78
Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol (2014) 0.78
Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea. Clin Gastroenterol Hepatol (2014) 0.78
Current developments in pharmacological therapeutics for chronic constipation. Acta Pharm Sin B (2015) 0.77
New treatment options for chronic constipation: mechanisms, efficacy and safety. Can J Gastroenterol (2011) 0.77
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists. Therap Adv Gastroenterol (2016) 0.76
Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol (2017) 0.75
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol (2015) 0.75
Irritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic Implications. Clujul Med (2014) 0.75
Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology (2016) 0.75
Review of efficacy and safety of laxatives use in geriatrics. World J Gastrointest Pharmacol Ther (2016) 0.75
Beneficial effect of sulphate-bicarbonate-calcium water on gallstone risk and weight control. World J Gastroenterol (2012) 0.75
Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome. World J Gastroenterol (2015) 0.75
The hospital anxiety and depression scale. Acta Psychiatr Scand (1983) 121.58
SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull (1973) 9.21
Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol (1997) 8.81
Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest (1971) 4.18
Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun (2005) 3.38
Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther (2002) 2.37
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol (2009) 2.25
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil (2009) 1.73
Bile acids in the diarrhoea of ileal resection. Gut (1973) 1.68
Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol Motil (2009) 1.62
Clinical decisions. Management of type 2 diabetes. N Engl J Med (2008) 1.58
Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med (1979) 1.57
Bile acids and colonic motility in the rabbit and the human. Gut (1975) 1.53
Effect of different doses of chenodeoxycholic acid on bile-lipid composition and on frequency of side-effects in patients with gallstones. Lancet (1974) 1.44
The proximal colonic motor response to rectal mechanical and chemical stimulation. Am J Physiol Gastrointest Liver Physiol (2002) 1.38
Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil (2009) 1.35
Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol (2008) 1.25
Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr (2008) 1.21
Bile acid malabsorption as a cause of chronic diarrhea: diagnostic value of 7alpha-hydroxy-4-cholesten-3-one in serum. Dig Dis Sci (1999) 1.19
Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. Dig Dis Sci (2007) 1.19
Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit. Am J Dig Dis (1976) 1.19
Recent advances in the understanding of bile acid malabsorption. Br Med Bull (2009) 1.18
Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. Scand J Gastroenterol (2008) 1.07
Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs (1981) 1.06
Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil (2004) 1.00
Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med (1998) 0.99
Dose-related effects of chenodeoxycholic acid in the rabbit colon. Dig Dis Sci (1980) 0.99
Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study. Gastroenterology (1983) 0.89
Treatment of constipation with chenodeoxycholic acid. J Int Med Res (1983) 0.88
Effects of chenodeoxy- and ursodeoxycholic acid on absorption, secretion and permeability in rat colon and small intestine. Digestion (1980) 0.83
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med (2003) 6.82
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 4.89
Chronic constipation. N Engl J Med (2003) 4.58
Circulating osteoblast-lineage cells in humans. N Engl J Med (2005) 4.19
Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A (2005) 4.03
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc Natl Acad Sci U S A (2007) 3.24
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant (2005) 2.12
Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07
Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care (2009) 2.01
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93
Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology (2002) 1.80
Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol (2012) 1.80
The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology (2008) 1.77
Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics (2003) 1.76
A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol (2004) 1.75
Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab (2011) 1.71
Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol (2008) 1.70
Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69
Increasing incidence of celiac disease in a North American population. Am J Gastroenterol (2013) 1.69
A system model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng (2006) 1.66
Fast-Find: a novel computational approach to analyzing combinatorial motifs. BMC Bioinformatics (2006) 1.66
Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol (2003) 1.66
A prospective, randomized, double-blind, placebo-controlled trial of endoscopic steroid injection therapy for recalcitrant esophageal peptic strictures. Am J Gastroenterol (2005) 1.64
Subsite-specific risk factors for esophageal and gastric adenocarcinoma. Am J Gastroenterol (2007) 1.63
Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol (2002) 1.58
Incidence of pelvic floor repair after hysterectomy: A population-based cohort study. Am J Obstet Gynecol (2007) 1.56
Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology (2010) 1.54
Continuous 12-lead electrocardiographic monitoring in an emergency department chest pain unit: an assessment of potential clinical effect. Ann Emerg Med (2003) 1.54
Effect of alginate on satiation, appetite, gastric function, and selected gut satiety hormones in overweight and obesity. Obesity (Silver Spring) (2009) 1.52